INTRAFRACTION PROSTATE MOTION MANAGEMENT
The raypilot system
Enabling accuracy in prostate cancer care
The Raypilot System is an electromagnetic positioning system that continuously localizes the prostate during radiation therapy. The system includes a transmitter which tracks the prostate tumour movements and outlines the urethra in real-time 3D, thus enhancing treatment precision and enabling a significant reduction of the risk of damaging surrounding healthy tissue. The precision makes it possible to use higher radiation dose and treatment may be given in a week or less, compared to conventional therapy over an 8-week period.
Healthcare professionals about Raypilot
“The reported significantly increased toxicity for SBRT vs standard IMRT was mostly urethra related. Having the possibility to identify the urethra using the Raypilot Hypocath gives us the opportunity to reduce the urethral dose without underdosing the tumour, thus delivering a safer treatment.”
Medical Physicist Denis Panizza, San Gerardo Hospital, Monza, Italy
“Raypilot Hypocath enables us to keep track of prostate motion during SBRT treatments where the precise dose to the target and strict tolerance to the surrounding organs is paramount.”
Professor Stefano Arcangeli, Head of Radiation Oncology, San Gerardo Hospital, Monza, Italy
BENEFITS
PATIENT STORIES
– I have not had any side effects. My way of life hasn´t changed at all.
Mr Cattaneo Giorgio, treated at San Gerardo Hospital in Monza, Italy.
Meet 79-year-old Mr Cattaneo Giorgio. He was treated for prostate cancer in four sessions performed in four consecutive days. The use of Raypilot allows faster as well as more effective and safe treatments.
-
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial
latest publications
-
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial
Read article
-
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
Read article
-
News
Patient Story: The Precision Study
·
First Patient Treated in the Precision Study British 71-year old prostate cancer patient treated in Spring 2025 The patient had no symptoms when he first requested a PSA test as […]
Events
SASRO 2025
We’re excited to participate in the 29th Annual SASRO Meeting, taking place from September 11–13 in the scenic mountain town of Davos.Our team will be present on-site, along with clinical […]
BUG 22nd Annual Meeting 2025
We look forward to joining the BUG 22nd Annual Meeting which takes place from Friday 12 – Saturday 13 September 2025 in Birmingham at the Hilton Birmingham Metropole. BUG brings […]
Webinar: Augmented SBRT for Prostate Cancer
Join leading experts as they present advanced accuracy techniques and innovative strategies to enhance and improve outcomes in prostate cancer treatment. Confirmed Speakers: Additional speakers may be announced soon. Join […]
NEWSLETTER
Follow us on LinkedIn
Let’s keep in touch